The American Society of Clinical Oncology and the International Association for the Study of Lung Cancer have formed a collaboration to introduce lung cancer reporting measures in Brazil.
NIH has awarded $20 million total to fund five additional hubs designed to speed up the translation of biomedical discoveries into commercially viable diagnostics, devices, therapeutics and tools to improve patient care and enhance health.
The Office of Hematology and Oncology Products at FDA has been renamed the Office of Oncologic Diseases—a move that includes an internal reorganization of divisions, as part of modernization plans approved in September 2019.
Norman E. Sharpless has returned to his previous role of NCI director earlier this week after serving as acting FDA commissioner since April 5.
Texans have approved an additional $3 billion in state funds for the Cancer Prevention and Research Institute of Texas, extending the institute's operations well past its sunset date in 2023.
David H. Thompson, a professor at the Department of Chemistry at Purdue University and a member of the Purdue Center for Cancer Research, is working on a better and faster way to produce drugs and eliminate shortages.
Lomustine, a.k.a. CCNU, is an old cancer drug.
FDA approves indication for Zejula in advanced ovarian, fallopian tube, or primary peritoneal cancer
FDA approved GlaxoSmithKline's Zejula (niraparib) for treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer.
FDA approved myChoice CDx for use as a companion diagnostic to identify women with advanced ovarian cancer who are candidates for Zejula (niraparib) in the late-line treatment setting.
The European Commission approved a dosing schedule for Bristol-Myers Squibb's Opdivo (nivolumab) as adjuvant treatment in adult melanoma patients with lymph node involvement or metastatic disease who have undergone complete resection.
